BetterLife Pharma Inc. (BETR.CN)
CAD 0.11
(0.0%)
CAD 0.11
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.02 Million CAD | 5.42% |
| 2022 | 7.6 Million CAD | 50.89% |
| 2021 | 5.04 Million CAD | -15.24% |
| 2020 | 5.94 Million CAD | 6.34% |
| 2019 | 5.59 Million CAD | 9.99% |
| 2018 | 5.08 Million CAD | 860.55% |
| 2017 | 529.51 Thousand CAD | -74.86% |
| 2016 | 2.1 Million CAD | 246.26% |
| 2015 | 608.17 Thousand CAD | 755.94% |
| 2014 | 71.05 Thousand CAD | -90.62% |
| 2013 | 757.68 Thousand CAD | 11.31% |
| 2012 | 680.69 Thousand CAD | -33.75% |
| 2011 | 1.02 Million CAD | -65.39% |
| 2010 | 2.96 Million CAD | 19945.26% |
| 2009 | 14.8 Thousand CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.02 Million CAD | -6.37% |
| 2024 Q1 | 8.56 Million CAD | 6.82% |
| 2023 Q4 | 8.02 Million CAD | 11.6% |
| 2023 FY | 8.02 Million CAD | 5.42% |
| 2023 Q1 | 7.12 Million CAD | -6.36% |
| 2023 Q2 | 7.37 Million CAD | 3.51% |
| 2023 Q3 | 7.18 Million CAD | -2.54% |
| 2022 Q2 | 7.02 Million CAD | 7.1% |
| 2022 Q1 | 6.56 Million CAD | 30.15% |
| 2022 Q4 | 7.6 Million CAD | 10.28% |
| 2022 Q3 | 6.89 Million CAD | -1.84% |
| 2022 FY | 7.6 Million CAD | 50.89% |
| 2021 Q2 | 4.41 Million CAD | -16.25% |
| 2021 Q3 | 3.78 Million CAD | -14.14% |
| 2021 Q4 | 5.04 Million CAD | 33.15% |
| 2021 FY | 5.04 Million CAD | -15.24% |
| 2021 Q1 | 5.26 Million CAD | -11.47% |
| 2020 Q2 | 4.28 Million CAD | 12.38% |
| 2020 FY | 5.94 Million CAD | 6.34% |
| 2020 Q4 | 5.94 Million CAD | -42.92% |
| 2020 Q1 | 3.81 Million CAD | -31.85% |
| 2020 Q3 | 10.42 Million CAD | 143.23% |
| 2019 Q2 | 1.37 Million CAD | -77.79% |
| 2019 FY | 5.59 Million CAD | 9.99% |
| 2019 Q4 | 5.59 Million CAD | 277.88% |
| 2019 Q3 | 1.48 Million CAD | 7.83% |
| 2019 Q1 | 6.18 Million CAD | 21.52% |
| 2018 FY | 5.08 Million CAD | 860.55% |
| 2018 Q4 | 5.08 Million CAD | 6.18% |
| 2018 Q2 | 5.58 Million CAD | 3.01% |
| 2018 Q1 | 5.42 Million CAD | 924.0% |
| 2018 Q3 | 4.78 Million CAD | -14.24% |
| 2017 Q2 | 1.64 Million CAD | -32.97% |
| 2017 FY | 529.51 Thousand CAD | -74.86% |
| 2017 Q4 | 529.51 Thousand CAD | 17.18% |
| 2017 Q3 | 451.86 Thousand CAD | -72.54% |
| 2017 Q1 | 2.45 Million CAD | 16.6% |
| 2016 Q3 | 1.86 Million CAD | 97.77% |
| 2016 Q2 | 943.18 Thousand CAD | 33.26% |
| 2016 FY | 2.1 Million CAD | 246.26% |
| 2016 Q4 | 2.1 Million CAD | 12.9% |
| 2016 Q1 | 707.77 Thousand CAD | 16.38% |
| 2015 Q1 | 95 Thousand CAD | 33.71% |
| 2015 FY | 608.17 Thousand CAD | 755.94% |
| 2015 Q4 | 608.17 Thousand CAD | 322.46% |
| 2015 Q3 | 143.95 Thousand CAD | 56.82% |
| 2015 Q2 | 91.8 Thousand CAD | -3.37% |
| 2014 FY | 71.05 Thousand CAD | -90.62% |
| 2014 Q4 | 71.05 Thousand CAD | -90.88% |
| 2014 Q3 | 778.83 Thousand CAD | 26.7% |
| 2014 Q2 | 614.71 Thousand CAD | 7.19% |
| 2014 Q1 | 573.48 Thousand CAD | -24.31% |
| 2013 Q3 | 784.7 Thousand CAD | 11.99% |
| 2013 Q1 | 666.27 Thousand CAD | -2.12% |
| 2013 Q2 | 700.67 Thousand CAD | 5.16% |
| 2013 FY | 757.68 Thousand CAD | 11.31% |
| 2013 Q4 | 757.68 Thousand CAD | -3.44% |
| 2012 Q2 | 559.28 Thousand CAD | 28.04% |
| 2012 FY | 680.69 Thousand CAD | -33.75% |
| 2012 Q4 | 680.69 Thousand CAD | 9.82% |
| 2012 Q3 | 619.84 Thousand CAD | 10.83% |
| 2012 Q1 | 436.8 Thousand CAD | -57.49% |
| 2011 Q4 | 1.02 Million CAD | 159.69% |
| 2011 Q3 | 395.63 Thousand CAD | -40.53% |
| 2011 Q2 | 665.22 Thousand CAD | -25.36% |
| 2011 Q1 | 891.21 Thousand CAD | -69.98% |
| 2011 FY | 1.02 Million CAD | -65.39% |
| 2010 FY | 2.96 Million CAD | 19945.26% |
| 2010 Q2 | 24.16 Thousand CAD | 6.57% |
| 2010 Q3 | 25 Thousand CAD | 3.45% |
| 2010 Q4 | 2.96 Million CAD | 11773.06% |
| 2010 Q1 | 22.67 Thousand CAD | 53.14% |
| 2009 FY | 14.8 Thousand CAD | 0.0% |
| 2009 Q4 | 14.8 Thousand CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 2.71 Million CAD | -194.898% |
| Asep Medical Holdings Inc | 3.05 Million CAD | -162.807% |
| BioVaxys Technology Corp. | 3.48 Million CAD | -130.108% |
| ChitogenX Inc. | 6.71 Million CAD | -19.495% |
| Rapid Dose Therapeutics Corp. | 5.04 Million CAD | -59.039% |
| Defence Therapeutics Inc. | 4.06 Million CAD | -97.454% |
| Entheon Biomedical Corp. | 85.32 Thousand CAD | -9299.845% |
| Gemina Laboratories Ltd. | 3.04 Million CAD | -163.704% |
| Glow Lifetech Corp. | 2.34 Million CAD | -241.86% |
| Lexston Life Sciences Corp. | 39.86 Thousand CAD | -20017.164% |
| Pharmala Biotech Holdings Inc. | 1.02 Million CAD | -679.431% |
| Doseology Sciences Inc. | 82.49 Thousand CAD | -9622.776% |
| MYND Life Sciences Inc. | 5.77 Million CAD | -38.89% |
| Nova Mentis Life Science Corp. | 841.66 Thousand CAD | -852.937% |
| PharmaTher Holdings Ltd. | 252.9 Thousand CAD | -3071.404% |
| PreveCeutical Medical Inc. | 5.95 Million CAD | -34.58% |
| Telescope Innovations Corp. | 1.35 Million CAD | -493.66% |